

## **EXECUTIVE TEAM**

### **Magnus Medical, Inc.**

#### **Brett Wingeier, Ph.D.**

**Co-founder and Chief Executive Officer**

**Member, Board of Directors**

Brett Wingeier, Ph.D., is co-founder and chief executive officer of Magnus Medical and a member of its Board of Directors. He brings over 20 years of experience in the development and commercialization of advanced neurotechnology. Most recently, he was a co-founder of Halo Neuroscience, where he was chief technology officer and later assumed the additional role of CEO. During his tenure at Halo, he raised \$26 million over seven years to commercialize non-invasive electrical brain stimulation across consumer and medical applications. He was also the architect of Halo Sport, the world's first consumer neurostimulation headset for movement training, as well as the company's next-generation products, which remain under development for cognitive and psychiatric health. As CTO, he built and supervised hardware and software development teams, led Halo's applied neuroscience research program, led manufacturing operations in the U.S. and Asia, and managed IP and regulatory affairs. As CEO, he additionally supervised clinical affairs, distribution, e-commerce, direct-to-consumer sales, partnerships, marketing, and customer support for Halo's portfolio of products.

Before co-founding Halo, Dr. Wingeier was one of the first employees at NeuroPace, where he co-developed the world's first responsive neurostimulator for epilepsy—called the RNS System—which received PMA approval from the U.S. Food & Drug Administration (FDA) in 2013. At NeuroPace, he was the principal biomedical engineer responsible for firmware engineering, clinical science, biostatistics, and product management. Today, the RNS System is an accepted treatment for intractable epilepsy, with over 2,000 implants and 82% seizure frequency reduction. In parallel, he was instrumental in the development and clinical trial of Autonomic Technologies' Pulsante implant, which attained CE Mark certification to treat cluster headaches in 2012, and migraine headaches in 2017.

Dr. Wingeier received a Bachelor of Science in Biomedical Engineering and his Ph.D. in Biomedical Engineering, both from Tulane University. He has completed additional studies at Swinburne University's Brain Science Institute and at Stanford Biodesign. Dr. Wingeier is a registered patent agent, a prolific inventor with over 60 issued U.S. patents, and a member of the IEEE Working Group on Neuroethics.

#### **Brandon Bentzley, M.D., Ph.D.**

## **Co-founder and Chief Scientific Officer**

Brandon Bentzley, M.D., Ph.D., is a co-founder and chief scientific officer of Magnus Medical. His interest in neuroscience led him to begin the Medical Scientist Training Program at the Medical University of South Carolina (MUSC), which is the birthplace of clinical transcranial magnetic stimulation (TMS) for the treatment of neuropsychiatric disorders. At MUSC, he completed his dissertation research with Gary Aston-Jones, Ph.D., studying the behavioral economics and neuroeconomics of substance use disorders. Simultaneously, he conducted clinical research on buprenorphine maintenance therapy, focusing on how patient perspectives influence treatment. He completed his residency in adult psychiatry and his postdoctoral training at Stanford University, where he focused on the development of SAINT technology. Dr. Bentzley has published articles in high-impact peer-reviewed journals, including *Brain*, *American Journal of Psychiatry*, *Molecular Psychiatry*, *Biological Psychiatry*, *Journal of Neuroscience*, *Journal of the American Medical Association Network Open*, and *Proceedings of the National Academy of Sciences of the United States of America*.

In parallel with his clinical work, Dr. Bentzley has over 15 years of experience in developing advanced automated systems that range from plasma reactors used in variable gravity experiments at NASA, to high-powered magnetically confined plasma reactors at Princeton University. He has developed and built a highly advanced neuro-behavioral recording system, which is currently in full-time use at the Malenka Lab in the Department of Psychiatry at Stanford Medicine.

Dr. Bentzley received a Bachelor of Science in Physics from The College of New Jersey, and his M.D. and Ph.D. from MUSC. His academic appointments include Clinical Assistant Professor in Psychiatry and Behavioral Sciences at Stanford University School of Medicine. His areas of clinical focus are treatment-resistant depression, substance abuse disorders, and suicidality.

## **Scott Ashworth Chief Commercial Officer**

Scott Ashworth joined Magnus Medical as chief commercial officer with over 30 years of leadership experience in the medical device and health care data industries with Fortune 500 and startup organizations. Most recently, he was CCO for DocSpera, a pre-and post-operative care coordination platform addressing care continuum challenges facing procedural specialists and OR professionals. Previous to DocSpera, Mr. Ashworth was vice president of sales at Hearst Health, where he led record sales growth year over year for their largest drug data business. Prior to joining Hearst Health, Mr. Ashworth was head of global sales for Gauss Surgical, a leading developer of computer vision applications for health care. At Gauss, he successfully built and supported sales teams throughout the U.S. to meet the ever-changing hospital, imaging, data, and product demands.

Mr. Ashworth's previous tenures also include senior executive positions at HeartFlow, Siemens Medical, and HP Healthcare, which was acquired by Philips Medical. At HeartFlow, he was the company's first vice president of global marketing and sales, building the commercial foundation for a transformative SaaS image mapping and service business model that included an initial strategic investment and distribution partnership with GE Medical. HeartFlow announced it would go public in 2021, valued at \$2.4 billion. While at Siemens, Mr. Ashworth held several sales and marketing management roles and was ultimately promoted to vice president of worldwide sales and service, where he was responsible for \$800 million in revenue.

In parallel, Mr. Ashworth has served on the Founders Board at StartX since 2015, a non-profit Stanford University-affiliated incubator made up of serial entrepreneurs, industry experts, tenured Stanford professors, and 700+ well-funded growth-stage startups. He earned a Bachelor of Arts in Economics and a minor in Kinesiology from the University of California, Los Angeles.

**Timothy J. Hale**  
**Vice President of Marketing**

Timothy J. Hale joined Magnus Medical as vice president of marketing, contributing over 20 years of medical device and pharmaceutical industry expertise in launching and commercializing disruptive technologies and indications. Before joining Magnus, he was the senior director of global marketing for AngioDynamics, where he led the commercial launch of the Auryon laser atherectomy system, an innovative treatment for peripheral artery disease. The launch won multiple awards for marketing excellence. Prior to AngioDynamics, he was senior director of marketing at Neuronetics for NeuroStar Advanced Therapy, a transcranial magnetic stimulation therapy for major depression. At Neuronetics, he drove physician-focused marketing and strategic planning and execution that resulted in three consecutive years of 28% growth year over year.

Mr. Hale also held a senior marketing position at Spectranetics (now part of Philips), where he helped to launch the Coronary Division, as well as develop and launch their flagship peripheral atherectomy product. His previous tenures also include management positions at AngioDynamics, The Selva Group, LLC, and LungRx, as well as sales and training positions at Boehringer Ingelheim Pharmaceutical Inc., Forest Pharmaceuticals, and ADT Security Service.

Mr. Hale earned a Bachelor of Science in Biology from Le Moyne College, a Master of Business Administration, Marketing Management from Colorado State University, and a Digital Marketing Professional certification from the Digital Marketing Institute.

**Erica Lundmark**  
**Vice President of Hardware Engineering**

Erica Lundmark joined Magnus Medical as vice president of hardware engineering with over 20 years of engineering experience in the medical device industry and a focus on hardware, systems, electrical, wireless communications, and medical standards compliance for both startups and mid-sized companies. Prior to joining Magnus, she was senior director of electrical engineering for InCube Labs, where she helped lead the team through characterization, verification, manufacture, and knowledge transfer of an active rechargeable implantable medical device and its associated external products for the treatment of pain. Ms. Lundmark was also senior director of electrical engineering for Sacramed, an InCube Labs early-stage company developing a neuromodulation system for the treatment of overactive bladder.

Ms. Lundmark's previous tenures also include senior management and engineering positions at NeuroPace and St. Jude Medical (formerly Ventritex). At NeuroPace, she worked within a small team of design engineers to develop an implantable responsive neurostimulator (RNS) and peripheral external products from design stage through technical support of a successful FDA submission for the treatment of epilepsy.

Ms. Lundmark earned a Bachelor of Science in Electrical Engineering from the University of California, Davis and a Master of Science in Biomedical Engineering from California State University, Sacramento.

**Romain Moreau-Gobard**  
**Vice President of Software Engineering**

Romain Moreau-Gobard joined Magnus Medical as vice president of software engineering, contributing over 20 years of experience in the development of advanced medical imaging software for both startups and established multinational companies. Before joining Magnus, he was vice president of software engineering for Advanced Scanners, where he led the development of 3D reconstruction and imaging algorithms for a novel structured light scanner for brain and spine imaging. Prior to this, Mr. Moreau-Gobard led software engineering teams at HeartFlow, where he designed a novel SAMD (software as a medical device) product to determine the fractional flow reserve from cardiac computed tomography (CT) scans, allowing entirely non-invasive detection and diagnosis of heart disease. HeartFlow's software received U.S. Food & Drug Administration (FDA) clearance in 2014, and in 2021, the company announced it would go public with a valuation of \$2.4 billion. Mr. Moreau-Gobard has also held engineering leadership roles at Siemens Medical and Siemens Corp. Technology.

Mr. Moreau-Gobard received a Master of Science in Artificial Intelligence from EPITA, the School of Engineering and Computer Science in Paris, France, and a Master of Science in

Management of Information Systems from Stevens Institute of Technology. He currently holds 15 U.S. and international patents.

**Tammy Morton**  
**Vice President of Clinical Affairs**

Tammy Morton brings more than 20 years of experience in planning and executing clinical trials to support regulatory submissions for class II and class III medical devices in a variety of therapeutics for both large corporations and startups. Ms. Morton has consulted for Magnus Medical since May 2021, providing expertise in clinical trial strategy, planning, and execution of studies, and in January 2022, she joined the company as its vice president of clinical affairs. Before joining Magnus full time, Ms. Morton was also the head of clinical affairs for CapsoVision, Inc., where she implemented the study design, operational planning, and execution for future regulatory approval of a colon capsule endoscope. Prior to joining CapsoVision, Ms. Morton was vice president of clinical affairs for Halo Neuroscience, the developer of home-use neurostimulation technology, where she was instrumental in planning the company's clinical strategy for major depressive disorder. Before joining Halo, she was vice president of clinical affairs for Radial Medical, where she planned and executed pre-market clinical trials in deep vein thrombosis, venous leg ulcer, and restless legs syndrome therapeutics. Her previous tenures also include senior management positions in clinical affairs at Gynesonics, Abbott Vascular, and Bailer Research, as well as a clinical research instructor at the University of California, Santa Cruz.

Ms. Morton earned a Bachelor of Science in Zoology from the University of California, Davis and a Master of Science in Exercise Physiology from California State University, Sacramento.

**Joost de Schutter**  
**Vice President of Finance**

Joost de Schutter joined Magnus Medical as vice president of finance, contributing over 25 years of experience in healthcare technology and life sciences for both Fortune 500 companies and startups. Most recently, Mr. de Schutter was vice president of finance for HeartFlow, where he successfully guided the company through its transition to public company readiness. Previously, he was vice president of finance for Thermo Fisher Scientific's Clinical Diagnostics Division, where he partnered with the global division's executive team to drive revenue growth and margin expansion while managing all aspects of the finance function. His previous tenures also include multiple senior management positions, including vice president, corporate controller for Prysm, consulting CFO for RenovoRX, an early-stage medical device start-up, and various finance leadership positions at Philips Healthcare.

Mr. de Schutter earned a Bachelor of Science in Business Economics from Erasmus University Rotterdam, and an international Executive Master of Finance and Control (iEMFC) from both the University of Maastricht, The Netherlands, and Washington University, St. Louis, receiving the Certified Controller title.

# # #